Blog
RSS FeedPosted by Michael Wonder on 21 Nov 2022
Big pharma may have to reveal government deals in WHO's draft pandemic rules
17 November 2022 - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make ...
Posted by Michael Wonder on 11 Nov 2022
EQRx no longer seeks to disrupt prices in non-small-cell lung cancer space
10 November 2022 - The biotechnology company EQRx no longer seeks to disrupt prices in the non-small-cell lung cancer space. ...
Posted by Michael Wonder on 21 Oct 2022
Pfizer COVID vaccine price hike to boost revenue for years, rivals may follow
21 October 2022 - Pfizer's plan to as much as quadruple US prices for its COVID-19 vaccine next year is ...
Posted by Michael Wonder on 10 Feb 2022
Eli Lilly promises 40% discount for Innovent’s PD-1 in last-ditch bid to shift FDA review to drug pricing
10 February 2022 - Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics partnered PD-1 ...
Posted by Michael Wonder on 21 Aug 2021
Competition, consolidation and evolution in the pharmacy market
12 August 2021 - Implications for efforts to contain drug prices and spending. ...
Posted by Michael Wonder on 31 Jul 2021
FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?
29 July 2021 - In a long-awaited move, the FDA has approved the first so-called interchangeable biosimilar version of insulin, ...
Posted by Michael Wonder on 24 Jun 2021
Biogen expects slow Alzheimer’s drug uptake, may reset price
24 June 2021 - Company faces uproar over $56,000 a year price tag for Aduhelm. ...
Posted by Michael Wonder on 13 Jun 2021
Unaffordable treatment for severe malaria highlights U.S. drug market pitfalls
11 June 2021 - When Eli Lilly announced in 2017 that it would stop producing quinidine, it was the only ...
Posted by Michael Wonder on 08 Jun 2021
Biogen faces tough questions over $56,000 a year price of newly approved Alzheimer’s drug
8 June 2021 - The biotech company’s price for the drug is higher than the $10,000 to $25,000 some Wall Street ...
Posted by Michael Wonder on 08 Jun 2021
Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years
7 June 2021 - Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year ...
Posted by Michael Wonder on 08 Jun 2021
Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate
8 June 2021 - It has all the makings of a bombastic drug pricing debate: a highly anticipated drug, widespread ...
Posted by Michael Wonder on 06 Jun 2021
The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price.
3 June 2021 - When Amber Freed heard in 2020 that a drug might help save her young child from ...
Posted by Michael Wonder on 25 Nov 2020
Third major COVID-19 vaccine shown to be effective and cheaper
24 November 2020 - Drugmaker AstraZeneca said late-stage trials showed its COVID-19 vaccine is highly effective, buoying the prospects of a ...
Posted by Michael Wonder on 02 Nov 2020
Takeda price hikes for a GI drug may give some patients another kind of stomachache
2 November 2020 - Two weeks ago, Takeda Pharmaceuticals raised the list price of its Entyvio treatment for ulcerative colitis ...
Posted by Michael Wonder on 22 Oct 2020
Remdesivir’s hefty price tag ignores NIH investment in its creation
22 October 2020 - Throughout the Democratic presidential primary, candidates cast a spotlight on the broken U.S. health care system ...